It has been hypothesized that there is a reduced AT2 cells number with low ability to synthesize and secrete endogenous surfactant in COVID-19 patients. To our knowledge, exogenous surfactant replacement has not been described so far in COVID-19 patients. We here report five cases of critically ill COVID-19 undergoing exogenous surfactant instillation through the airways.
Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia / Busani, S; Dall’Ara, L; Tonelli, R; Clini, E; Munari, E; Venturelli, S; Meschiari, M; Guaraldi, G; Cossarizza, A; Ranieri, Mv; Girardis, M.. - In: THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE. - ISSN 1753-4658. - 14:(2020), pp. 1-6. [10.1177/1753466620951043]
Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia.
Busani, S
;Tonelli, R;Clini, E;Munari, E;Venturelli, S;Meschiari, M;Guaraldi, G;Cossarizza, A;Girardis, M.
2020
Abstract
It has been hypothesized that there is a reduced AT2 cells number with low ability to synthesize and secrete endogenous surfactant in COVID-19 patients. To our knowledge, exogenous surfactant replacement has not been described so far in COVID-19 patients. We here report five cases of critically ill COVID-19 undergoing exogenous surfactant instillation through the airways.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Busani (Surfactant in COVID-19 pneumonia- 2020).pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
216.05 kB
Formato
Adobe PDF
|
216.05 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
